Boston Scientific Corporation (BSX) |
|
Price: $67.2400
$1.01
1.525%
|
Day's High:
| $66.77
| Week Perf:
| -0.37 %
|
Day's Low: |
$ 66.16 |
30 Day Perf: |
1.74 % |
Volume (M): |
305 |
52 Wk High: |
$ 68.07 |
Volume (M$): |
$ 20,245 |
52 Wk Avg: |
$54.87 |
Open: |
$66.06 |
52 Wk Low: |
$47.52 |
|
|
Market Capitalization (Millions $) |
98,661 |
Shares
Outstanding (Millions) |
1,467 |
Employees |
41,000 |
Revenues (TTM) (Millions $) |
14,241 |
Net Income (TTM) (Millions $) |
1,592 |
Cash Flow (TTM) (Millions $) |
-70 |
Capital Exp. (TTM) (Millions $) |
711 |
Boston Scientific Corporation
Boston Scientific Corporation is a worldwide developer, manufacturer and marketer
of medical devices whose products are used in a broad range of interventional
medical specialties, including interventional cardiology, peripheral interventions,
neurovascular intervention, electrophysiology, vascular surgery, endoscopy, oncology,
urology and gynecology. Since the Company was formed in 1979, it has advanced
the practice of less-invasive medicine by providing a broad portfolio of innovative
products, technologies and services across a wide range of medical specialties.
The Companys products are generally inserted into the human body through natural
openings or small incisions in the skin and can be guided to most areas of the
anatomy to diagnose and treat a wide range of medical problems. These products
help physicians and other medical professionals improve their patients quality
of life by providing alternatives to surgery.
The Companys broad innovative product offerings have enabled it to become a
leader in the interventional cardiology market. Leadership is in part due to
its coronary stent product offerings. Coronary stents are tiny, mesh tubes used
in the treatment of coronary artery disease and implanted in patients to prop
open arteries and facilitate blood flow from the heart. The Company, however,
looked to further enhance the outcomes associated with the use of coronary stents,
particularly the processes that lead to in-stent restenosis (the growth of neointimal
tissue within an artery after angioplasty and stenting), through dedicated internal
and external product development and scientific research. The Company believes
that the combination of certain drugs and coronary stents offers the opportunity
for a more lasting solution for coronary artery disease.
The Companys products are offered for sale by two dedicated business groups
- Cardiovascular and Endosurgery. The Cardiovascular organization focuses on
products and technologies for use in interventional cardiology, peripheral interventions,
vascular surgery, electrophysiology, and neurovascular procedures. The Endosurgery
organization focuses on products and technologies for use in oncology, endoscopy,
urology and gynecology procedures.
Boston Scientific announced a master branding initiative. This initiative marks
the Companys evolution from a collection of divisional identities into one,
unified organization. The master brand will enable the Company to strengthen
recognition of the Boston Scientific name and build equity in that name.
The Company sold its products to over 10,000 hospitals, clinics, out-patient
facilities and medical offices. The Company is not dependent on any single institution
The Company also distributes certain products for third parties, including
an introducer sheath, certain guidewires and acellular tissue for use in connection
with urology and gynecology procedures.
INTERNATIONAL OPERATIONS
Internationally, the Company operates through three business segments divided
among the geographic regions of Europe, Japan and Inter-Continental.
COMPETITION
The Company encounters significant competition across its product lines and
in each market in which its products are sold from various entities, some of
which may have greater financial and marketing resources than the Company. The
Companys primary competitors include: Abbott Laboratories, Inc., Cook, Inc.,
Guidant Corporation (including its subsidiary Advanced Cardiovascular Systems,
Inc.), Johnson & Johnson (including its subsidiary, Cordis Corporation),
and Medtronic, Inc. (including its subsidiary, Medtronic AVE, Inc.), as well
as a wide range of companies which sell a single or limited number of competitive
products or participate only in specific market segment.
Company Address: 300 Boston Scientific Way Marlborough 1752 MA
Company Phone Number: 683-4000 Stock Exchange / Ticker: NYSE BSX
|
|
Customers Net Income fell by |
BSX's Customers Net Profit Margin fell to |
-14.18 % |
2.19 %
|
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Stock Offering
Published Fri, Feb 23 2024 2:27 AM UTC
Boston Scientific Corporation (NYSE: BSX), a leading medical technology company, has announced the successful pricing of $2 billion in senior notes by its wholly owned finance subsidiary, American Medical Systems Europe B.V. This significant offering demonstrates the company's robust financial position and signals its continued commitment to innovation and growth i...
|
Boston Scientific Corporation
Axonics, Inc.'s definitive agreement to be acquired by Boston Scientific Corporation for the impressive sum of $3.7 billion marks a significant milestone in the field of urology medical devices. This game-changing deal is set to reshape the landscape of sacral neuromodulation therapy for bladder and bowel dysfunction, solidifying Boston Scientific's position in the market and expanding its product portfolio. With a strong commitment to innovation and improving patient outcomes, Boston Scientific's acquisition of Axonics is poised to drive advancements in urology medical devices and ultimately benefit patients worldwide. Boston Scientific Corporation, known for its dedication to research and development, operates with a business model focused on designing, developing, and manufacturing a wide range of medical devices across various medical specialties. With a global presence and robust sales and distribution networks, the company is able to effectively deliver its products to healthcare professionals and hospitals around the world. Boston Scientific's emphasis on introducing cutting-edge technologies and solutions to the market has positioned it as a leader in the medical device industry.
|
Merger and Acquisition
Published Mon, Jan 8 2024 12:00 PM UTC
Axonics Announces Definitive Agreement to be Acquired by Boston Scientific: A Game-Changing Deal Shaping the Future of Urology Medical Devices IRVINE, Calif. - In a landmark deal that is set to redefine the landscape of urology medical devices, Axonics, Inc. has announced its definitive agreement to be acquired by Boston Scientific Corporation for an impressive $3.7 bill...
|
Boston Scientific Corporation
Boston Scientific Corporation, a leading Medical Equipment & Supplies company, has reported strong financial results in the third quarter of 2023. The company's earnings per share (EPS) increased significantly by 183.33% to $0.34 per share, while revenue showed an impressive growth of 11.262% to $3.53 billion compared to the same period last year. These positive figures outperformed the overall industry trend, as Boston Scientific Corporation's contemporaries in the Medical Equipment & Supplies sector reported only a 0.80% business rise during the same period. This indicates the company's ability to effectively navigate market challenges and stand out in its industry.
|
Boston Scientific Corporation
Boston Scientific Corporation, a prominent player in the Medical Equipment & Supplies industry, has reported impressive financial performance in its most recent fiscal period. With revenue reaching $3.60 billion and earnings per share of $0.18, the company showcased substantial growth. Let's delve into the intriguing facts and figures that highlight Boston Scientific's exceptional performance. Robust Revenue Growth: Boston Scientific witnessed a remarkable revenue growth rate of 10.974% year-on-year. This considerable increase exceeded the industry average, positioning the company as a frontrunner in the Medical Equipment & Supplies sector. In contrast, most of its competitors in the same industry recorded a mere 2.18% growth during the same reporting season in the second quarter of 2023.
|
Per Share |
Current |
Earnings (TTM) |
1.03 $ |
Revenues (TTM) |
9.71 $
|
Cash Flow (TTM) |
- |
Cash |
0.59 $
|
Book Value |
13.31 $
|
Dividend (TTM) |
0.02 $ |
|
Per Share |
|
Earnings (TTM) |
1.03 $
|
Revenues (TTM) |
9.71 $ |
Cash Flow (TTM) |
- |
Cash |
0.59 $
|
Book Value |
13.31 $ |
Dividend (TTM) |
0.02 $ |
|
|
|
Cardiovascular |
|
Segment |
|
|
of total Revenue |
Electrophysiology |
|
Segment |
|
|
of total Revenue |
CARDIOVASCULAR GROUP |
|
Segment |
|
|
of total Revenue |
Endoscopy |
|
Segment |
|
|
of total Revenue |
TOTAL ENDOSURGERY |
|
Segment |
|
|
of total Revenue |
Neuromodulation |
|
Segment |
|
|
of total Revenue |
Cardiac Rhythm Management |
|
Segment |
|
|
of total Revenue |
|
|
|